NZ756678A - Anti-lag-3 antibodies and uses thereof - Google Patents
Anti-lag-3 antibodies and uses thereofInfo
- Publication number
- NZ756678A NZ756678A NZ756678A NZ75667818A NZ756678A NZ 756678 A NZ756678 A NZ 756678A NZ 756678 A NZ756678 A NZ 756678A NZ 75667818 A NZ75667818 A NZ 75667818A NZ 756678 A NZ756678 A NZ 756678A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibodies
- lag
- lag3 binding
- block lag3
- lsectin
- Prior art date
Links
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 4
- 102000017578 LAG3 Human genes 0.000 abstract 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 abstract 2
- 102100028666 C-type lectin domain family 4 member G Human genes 0.000 abstract 1
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 101000766915 Homo sapiens C-type lectin domain family 4 member G Proteins 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004073 interleukin-2 production Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/074365 WO2018152687A1 (en) | 2017-02-22 | 2017-02-22 | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
| CN2017088570 | 2017-06-16 | ||
| PCT/CN2018/076940 WO2018153340A1 (en) | 2017-02-22 | 2018-02-22 | Anti-lag-3 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ756678A true NZ756678A (en) | 2023-02-24 |
Family
ID=63253327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ756678A NZ756678A (en) | 2017-02-22 | 2018-02-22 | Anti-lag-3 antibodies and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10577421B2 (OSRAM) |
| EP (1) | EP3389702A4 (OSRAM) |
| JP (1) | JP6929951B2 (OSRAM) |
| KR (2) | KR102144317B1 (OSRAM) |
| CN (1) | CN109475617B (OSRAM) |
| AU (1) | AU2018226298B2 (OSRAM) |
| CA (1) | CA3053989C (OSRAM) |
| IL (1) | IL268734A (OSRAM) |
| NZ (1) | NZ756678A (OSRAM) |
| SG (1) | SG11201907561PA (OSRAM) |
| WO (1) | WO2018153340A1 (OSRAM) |
| ZA (1) | ZA201905790B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI875679B (zh) | 2017-07-06 | 2025-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| CN110678484B (zh) * | 2018-08-21 | 2022-12-27 | 天境生物科技(杭州)有限公司 | 抗pd-l1/抗lag3双特异性抗体及其用途 |
| EP3833693A4 (en) * | 2018-08-21 | 2023-06-07 | ABL Bio Inc. | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
| CN110066334B (zh) * | 2019-03-22 | 2020-03-10 | 南京医科大学 | 抗Galectin-3的全人源化单域抗体及应用 |
| CN112010976B (zh) * | 2019-05-29 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗lag3抗体及其用途 |
| CN110320367A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院（广州呼吸中心） | 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用 |
| KR102444797B1 (ko) * | 2019-06-14 | 2022-09-20 | 에이비엘바이오 주식회사 | α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도 |
| CN112513097B (zh) * | 2019-07-11 | 2021-10-29 | 武汉友芝友生物制药有限公司 | 四价对称双特异性抗体 |
| EP4039711A4 (en) * | 2019-07-23 | 2023-11-15 | Nanjing GenScript Biotech Co., Ltd. | BISPECIFIC ANTI-CD47/ANTI-LAG-3 ANTIBODY, PREPARATION METHOD AND USE THEREOF |
| CN113004407B (zh) * | 2019-12-20 | 2022-11-11 | 广东菲鹏制药股份有限公司 | Lag3抗体及其应用 |
| CN113348182B (zh) * | 2019-12-30 | 2022-07-12 | 上海海路生物技术有限公司 | Lag-3抗体及其医药用途 |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| CN116023484A (zh) * | 2020-05-19 | 2023-04-28 | 益科思特(北京)医药科技发展有限公司 | 抗新型冠状病毒Spike蛋白抗体及其应用 |
| CN114605544B (zh) * | 2020-06-05 | 2023-08-01 | 北京天广实生物技术股份有限公司 | Lag3抗体及其用途 |
| CN112062832B (zh) * | 2020-09-24 | 2021-08-03 | 河南赛诺特生物技术有限公司 | Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒 |
| CN114621345B (zh) * | 2020-12-10 | 2022-11-29 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CN115490764B (zh) * | 2021-06-18 | 2025-06-03 | 佛山热休生物技术有限公司 | Lgals3的表位肽及所述表位肽与热休克蛋白的复合物 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250198990A1 (en) * | 2022-03-15 | 2025-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of Identifying Anti-LAG-3 Agents |
| CN115819595B (zh) * | 2023-01-03 | 2023-05-16 | 上海百英生物科技股份有限公司 | 一种抗lag3纳米抗体及其制备方法与应用 |
| WO2024189628A1 (en) * | 2023-03-16 | 2024-09-19 | Technion Research And Development Foundation Limited | Lag-3 inhibition for enhanced antiviral immune response |
| WO2024196072A1 (ko) * | 2023-03-20 | 2024-09-26 | 경북대학교 산학협력단 | Lag-3에 결합하는 펩타이드 및 이의 용도 |
| WO2025040080A1 (en) * | 2023-08-21 | 2025-02-27 | Beigene Switzerland Gmbh | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy |
| US20250197493A1 (en) * | 2023-12-13 | 2025-06-19 | Eli Lilly And Company | Lag-3 agonist antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| MY210104A (en) * | 2013-03-15 | 2025-08-27 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
| CN106029694A (zh) * | 2013-12-06 | 2016-10-12 | 达纳-法伯癌症研究院公司 | 治疗性肽 |
| EP3660050A1 (en) * | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MA41463A (fr) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| TWI733687B (zh) * | 2015-07-22 | 2021-07-21 | 美商索倫多醫療公司 | 結合ｌａｇ３之抗體治療劑 |
| SG10202010506TA (en) * | 2015-07-30 | 2020-11-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
-
2018
- 2018-02-22 AU AU2018226298A patent/AU2018226298B2/en active Active
- 2018-02-22 CN CN201880000932.2A patent/CN109475617B/zh active Active
- 2018-02-22 KR KR1020187022954A patent/KR102144317B1/ko active Active
- 2018-02-22 US US16/069,487 patent/US10577421B2/en active Active
- 2018-02-22 CA CA3053989A patent/CA3053989C/en active Active
- 2018-02-22 SG SG11201907561PA patent/SG11201907561PA/en unknown
- 2018-02-22 KR KR1020197014275A patent/KR102236259B1/ko active Active
- 2018-02-22 EP EP18733152.5A patent/EP3389702A4/en not_active Withdrawn
- 2018-02-22 NZ NZ756678A patent/NZ756678A/en unknown
- 2018-02-22 WO PCT/CN2018/076940 patent/WO2018153340A1/en not_active Ceased
- 2018-02-22 JP JP2019544658A patent/JP6929951B2/ja active Active
-
2019
- 2019-08-15 IL IL26873419A patent/IL268734A/en unknown
- 2019-09-02 ZA ZA2019/05790A patent/ZA201905790B/en unknown
- 2019-11-18 US US16/687,387 patent/US11414485B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200071403A1 (en) | 2020-03-05 |
| AU2018226298A1 (en) | 2019-09-19 |
| CA3053989C (en) | 2024-10-29 |
| CN109475617A (zh) | 2019-03-15 |
| US20190225687A1 (en) | 2019-07-25 |
| WO2018153340A1 (en) | 2018-08-30 |
| US11414485B2 (en) | 2022-08-16 |
| AU2018226298B2 (en) | 2022-02-17 |
| IL268734A (en) | 2019-10-31 |
| CN109475617B (zh) | 2022-05-17 |
| EP3389702A4 (en) | 2019-08-14 |
| ZA201905790B (en) | 2025-03-26 |
| EP3389702A1 (en) | 2018-10-24 |
| KR102144317B1 (ko) | 2020-08-18 |
| US10577421B2 (en) | 2020-03-03 |
| KR20180113195A (ko) | 2018-10-15 |
| KR102236259B1 (ko) | 2021-04-06 |
| KR20190111894A (ko) | 2019-10-02 |
| SG11201907561PA (en) | 2019-09-27 |
| JP2020508303A (ja) | 2020-03-19 |
| JP6929951B2 (ja) | 2021-09-01 |
| CA3053989A1 (en) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ756678A (en) | Anti-lag-3 antibodies and uses thereof | |
| PH12021550764A1 (en) | Trem2 stabilizing antibodies | |
| PH12020500078A1 (en) | Anti-ctla-4 antibodies and uses thereof | |
| WO2019157366A8 (en) | Antibody variable domains targeting the nkg2d receptor | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| NZ774111A (en) | Antibodies binding to cd3 | |
| PH12021553145A1 (en) | Multispecific heavy chain antibodies binding to cd22 and cd3 | |
| PH12019500545A1 (en) | Cd3 binding antibodies | |
| MX2022007140A (es) | Terapias combinadas dirigidas a proteina 1 de muerte celular programada (pd-1), proteina 3 de dominio de mucina y dominio inmunoglobulina de los linfocitos t (tim-3), y gen de activacion de linfocitos 3 (lag-3). | |
| HK1254861A1 (zh) | 抗lag3抗体及其用途 | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| MX2021000708A (es) | Anticuerpos de cadena pesada que se unen al cd19. | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| JOP20190236A1 (ar) | أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد | |
| EA201890143A2 (ru) | Антитела против pdgfr-бета и их применения | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| MX2019002867A (es) | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. | |
| MX2018016183A (es) | Anticuerpos especificos del ligando 1 de muerte programada y metodos de uso de los mismos. | |
| EA202090387A1 (ru) | Белки, связывающие nkg2d, cd16 и flt3 | |
| MY160590A (en) | Cd127 binding proteins | |
| MX2020002612A (es) | Anticuerpos de la proteina de muerte celular programada 1. | |
| WO2017019957A3 (en) | Binding proteins and methods of use thereof | |
| MX2021009727A (es) | Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: I-MAB BIOPHARMA US LIMITED, US Effective date: 20191205 |
|
| ASS | Change of ownership |
Owner name: I-MAB BIOPHARMA (HANGZHOU) CO., LTD., CN Effective date: 20210422 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2025 BY HANNAH THOMAS Effective date: 20240130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2026 BY SABINE Effective date: 20250217 |